Replies to post #238154 on Biotech Values

[DewDiligence]

MYOV/PFE PR on FDA approval of Myfembree—(relugolix_combination_ tablet):

https://www.globenewswire.com/news-release/2021/05/26/2236871/0/en/Myovant-Sciences-and-Pfizer-Receive-FDA-Approval-for-MYFEMBREE-the-First-Once-Daily-Treatment-for-Heavy-Menstrual-Bleeding-Associated-With-Uterine-Fibroids.html

Based on the collaboration struck in Dec 2020 (#msg-160498061), MYOV and PFE will split profits 50/50 from US/Canada sales of Myfembree.

CC Friday at 8:30am ET.

[DewDiligence]

MYOV/PFE—What the FDA approved today was not Relugolix per se, but rather a fixed-dose-combination of Relugolix with estradiol and norethindrone.

Relugolix by itself was previously FDA-approved for prostate cancer under the brand name, Orgovyx (#msg-160319692).